Norbert Hollaender
About
In The Last Decade
Norbert Hollaender
25 papers receiving 3.9k citations
Hit Papers
Peers
Comparison fields: 5 of 94
- Pulmonary and Respiratory Medicine 2.5k
- Molecular Biology 2.4k
- Cancer Research 1.3k
- Oncology 1.0k
- Hematology 403
Countries citing papers authored by Norbert Hollaender
This map shows the geographic impact of Norbert Hollaender's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Norbert Hollaender with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Norbert Hollaender more than expected).
Fields of papers citing papers by Norbert Hollaender
This network shows the impact of papers produced by Norbert Hollaender. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Norbert Hollaender. The network helps show where Norbert Hollaender may publish in the future.
Co-authorship network of co-authors of Norbert Hollaender
This figure shows the co-authorship network connecting the top 25 collaborators of Norbert Hollaender. A scholar is included among the top collaborators of Norbert Hollaender based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Norbert Hollaender. Norbert Hollaender is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 1 | |
| 3 | 2 | |
| 4 | 8 | |
| 5 | 73 | |
| 6 | 33 | |
| 7 | 28 | |
| 8 | 23 | |
| 9 | 2 | |
| 10 | 2 | |
| 11 | 15 | |
| 12 | 102 | |
| 13 | Phase 3 trial of everolimus for metastatic renal cell carcinoma breakdown → | 903 |
| 14 | 3 | |
| 15 | 0 | |
| 16 | 2 | |
| 17 | Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial breakdown → | 2339 |
| 18 | 42 | |
| 19 | 14 | |
| 20 | Serious cutaneous adverse reactions differences in demography and past history of drug intake between Stevens-Johnson Syndrome /toxic epidermal necrolysis and generalized bullous fixed drug eruption | 5 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.